One thing investors wanted to hear on conference calls this earnings season was how companies are responding to Amazon. One industry that escaped such queries was defense, but that may have been…
Merck, Johnson & Johnson, DuPont, and Verizon led the 20 stocks that were heading for a lower close just minutes before the closing bell.
A blockbuster drug is about to get a chance to have even higher sales, as the FDA has expanded its approval of Imbruvica for the treatment of adult patients with chronic graft…
General Electric, Nike, Home Depot, and Johnson & Johnson led the DJIA lower Monday.
Stocks have pulled back a tad from all-time highs, and the market indexes were indicated to have a slight drop on Friday morning. Still, indexes remain right at all time highs and…
Major pharmaceutical companies have posted a relatively positive year so far. Currently, Johnson & Johnson (NYSE: JNJ) is leading the pack with Eli Lilly and Co. (NYSE: LLY) in a close second.…
Stocks were indicated marginally higher on Thursday after the European Central Bank statement remained quite dovish. The major equity indexes all remain just under all-time highs. Even though this bull market may…
Johnson & Johnson (NYSE: JNJ) released its fiscal second-quarter earnings report before the markets opened on Tuesday. The company posted $1.83 in earnings per share (EPS) on $18.8 billion in revenue. The…
Chris Lange 24/7 Wall St. has put together a preview of General Electric, Microsoft and other Dow Jones Industrial Average companies scheduled to report their quarterly results this coming week.
Johnson & Johnson and Merck were the top performers among the Dow 30 stocks Thursday while Goldman Sachs and Wal-Mart were the big laggards.
These are the top 20 stock buybacks in dollars spent during the first quarter of 2017 of all S&P 500 companies.
With a Federal Reserve rate hike decision, investors have to keep in mind what to think of the stock market heading into the rest of this summer and what to expect for…
Boeing, 3M, Johnson & Johnson, and Visa all posted new 52-week highs Friday to lead the DJIA's gain for the day.
When companies see their shares rise almost 50%, investors probably just assume the news is from a buyout or a merger. In Tuesday's massive gain in shares of Protagonist Therapeutics, it was…
Jon C. Ogg Protagonist Therapeutics saw its shares make a solid gain early on Tuesday after the company announced a key worldwide licensing and collaboration agreement with Janssen Biotech.
Chris Lange 